Serum Free Zinc as A Predictor for Excessive Function of Pancreatic Beta-Cells in Central-Obese Men

Rahman, Miftakh Nur; Sukmawati, Indriyanti Rafi; Puspitasari, Irma Melyani; Fattah, Miswar

doi:10.18585/inabj.v11i3.618

Cited by 2 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study observed the different mean scores of HOMA-β between the IR and non-IR groups and between two classes of BMI classes among benign neoplasm cases; meanwhile, there was no statistical difference among malignant cases. It was probably due to the lower prevalence of obese and overweight participants in the malignant group, thus making the marker measurement results less reliable ( 64 ).…”

Section: Discussionmentioning

confidence: 99%

“…HOMA-β classification depicts the function of the pancreatic β-cells ( 64 ). The classification used for the HOMA-β tests was determined by an Asian study from Japan using a cut-off point by tertile: ≤76.25 (low value; suggesting β-cell dysfunction); 76.25-122.13 (medium value; indicating normal β-cell function); and ≥122.13 (high; suggesting the excessive function of insulin secretion in β-cells, commonly found in central obesity) ( 53 ).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Is there any difference in insulin resistance status between cases of benign and malignant ovarian neoplasms? A study on surrogate markers of insulin resistance in Indonesian non‑diabetic women

et al. 2022

View full text Add to dashboard Cite

The association between insulin resistance (IR) and ovarian neoplasm is little known. The present study attempted to investigate the difference in clinicopathological characteristics, metabolic parameters, and IR prevalence between benign and malignant ovarian neoplasms. The cross-sectional study involved 52 non-diabetic women with benign (n=27) and malignant (n=25) diagnoses in a tertiary hospital in Indonesia. Fasting insulin level (FIL), homeostatic model assessment of IR and β-cell dysfunction (HOMA-IR and HOMA-β), fasting IR index (FIRI), and quantitative insulin sensitivity check index (QUICKI) were used as surrogate markers to evaluate IR. Parametric and nonparametric statistical tests were employed to analyze the different parameters between the two groups. Pearson or Spearman's rank test assessed the correlation between markers and clinical variables. Results revealed that patients with benign neoplasms were younger than those with malignant neoplasms (38.63 vs. 47.40 years; P=0.003) and had a higher median body mass index (BMI) than their counterparts (22.98 vs. 18.61 kg/m 2 ; P=0.014). Different characteristics between benign and malignant neoplasm cases were found in menopausal status, ovary side affected, systolic blood pressure, and BMI classes. Endometrial cysts and mucinous carcinoma were the most often diagnosed benign and malignant neoplasms. Malignant neoplasms had a lower median HOMA-β score than benign neoplasms (49.33 vs. 75.79; P=0.011), indicating more severe β-cell dysfunction. No significant difference was observed in the prevalence of IR between benign and malignant ovarian neoplasms for the following values of each marker: FIL (25.9% vs. 12.0%), HOMA-IR (37.0% vs. 28.0%), FIRI (51.9% vs. 48.0%) and QUICKI (81.5% vs. 92.0%). The indicators of FIL, HOMA-IR, HOMA-β, FIRI, and QUICKI correlated with each other and confirmed the reliability of these surrogate markers for measuring IR status in ovarian neoplasms. In brief, benign ovarian neoplasms tended to have more IR when compared with malignant ovarian neoplasms. However, this difference was not statistically significant.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Is there any difference in insulin resistance status between cases of benign and malignant ovarian neoplasms? A study on surrogate markers of insulin resistance in Indonesian non‑diabetic women

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Previous study showed that there was a good correlation between serum free Zn with HOMA-B, the concentration of serum free Zn increased along with HOMA-B and indicating the excessive function of beta cells and interestingly, it reduced dramatically in T2DM along the decrease beta cell function. (55) Based on that finding, Zn showed a potential feature to predict beta cell failure at the early stage of chronically beta cells stress when compensate the high demand of insulin in central obesity. The complete Zn features in beta cell protection from oxidative stress and inflammation and insulin production illustrated in Figure 5.…”

Section: The Role Of Scfas In Pancreatic Beta Cell Healthymentioning

confidence: 94%

Nutritional Biomarkers for Predicting Pancreatic Beta Cell Failure in Central Obesity

et al. 2021

Self Cite

View full text Add to dashboard Cite

BACKGROUND: There is a continuous rise in the prevalence of central obesity and become a pressing health problem in the world. Central obesity followed by many metabolic disorders especially Type 2 Diabetes Mellitus (T2DM). The pathogenesis started from overnutrition signal that force pancreatic beta cells to produce a large number of insulin. Low-grade chronic inflammation that occurred also affects the organs sensitivity against insulin and caused beta cells to compensated this situation and at the end become exhausted and loss its function.CONTENT: Along compensation mechanism, certain nutrients were support the beta cells to maintain their mass and function to produce insulin. Short chain fatty acids (SCFAs) are gut microbiota fermentation product that act as nutrient and give an advantage to the proliferation and survivability of the beta cells. Zinc (Zn) also plays an important role in every step of insulin production. Moreover, these nutrients protecting pancreas against inflammation and oxidative stress through certain mechanism. Most of patients with central obesity are unaware of the presence of this disturbance at early stage. Whereas, at molecular level there is a magnitude of SCFAs and Zn level in the blood that would become an early signal and predict the damage of beta cells.SUMMARY: Quantification of these two nutrients in the blood expected to provide an early warning tool to maintain insulin adequacy and predict the possibility of beta cell failure in central obesity with promising performance.KEYWORDS: central obesity, T2DM, SCFAs, Zinc, beta cell failure

show abstract

Serum Free Zinc as A Predictor for Excessive Function of Pancreatic Beta-Cells in Central-Obese Men

Cited by 2 publications

References 12 publications

Is there any difference in insulin resistance status between cases of benign and malignant ovarian neoplasms? A study on surrogate markers of insulin resistance in Indonesian non‑diabetic women

Is there any difference in insulin resistance status between cases of benign and malignant ovarian neoplasms? A study on surrogate markers of insulin resistance in Indonesian non‑diabetic women

Nutritional Biomarkers for Predicting Pancreatic Beta Cell Failure in Central Obesity

Contact Info

Product

Resources

About